Date: 2013-09-16
Type of information: Grant
Company: BioVersys (Switzerland) -University of Applied Sciences (ZHAW) (Switzerland), the University of Applied Science North Western Switzerland (FHNW) (Switzerland), Muttenz, and research groups of the Universities of Basel, Berne and Geneva (Switzerland)
Investors: Commission for Technology and Innovation (CTI) (Switzerland)
Amount: CHF 2.1 million
Funding type: grant
Planned used: The national Commission for Technology and Innovation (CTI) supports a research consortium for drug development to combat antibiotic resistances with an overall budget of CHF 2.1 million. The consortium consists of BioVersys AG, Basel, the Zurich University of Applied Sciences (ZHAW), Wädenswil, the University of Applied Science North Western Switzerland (FHNW), Muttenz, and research groups of the Universities of Basel, Berne and Geneva. BioVersys AG is leading the project as corporate partner, which is funded by the Commission of Technology and Innovation with a seven-digit contribution to develop new drugs to combat antibiotic resistances together with above mentioned Swiss research network in the areas of biology, chemistry and medicine. The collaborative project follows a new strategy in the fight against resistant bacteria. The goal is to develop a drug combination consisting of a novel class of therapeutic compounds called TRICs (Transcription Regulator Inhibitory Compound), which “switch off” bacterial resistance against a conventional antibiotic. The project should be finished in two to three years and lead to a clinical candidate molecule.
Others:
Therapeutic area: Infectious diseases
